 |
 Video: What is a Stock Split?
|
|
|
| Relay Therapeutics is a clinical-stage precision medicines company. Co. has deployed its technology platform to build a pipeline of product candidates to address targets in precision medicine where there is clear evidence linking target proteins to disease and where molecular diagnostics can identify relevant patients for treatment. Co. has initiated a clinical trial for one of its product candidates, RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced or metastatic FGFR2-altered solid tumors. The U.S. Food and Drug Administration has granted orphan drug designation to RLY-4008 for the treatment of cholangiocarcinoma. According to our Relay Therapeutics stock split history records, Relay Therapeutics has had 0 splits. | |
|
Relay Therapeutics (RLAY) has 0 splits in our Relay Therapeutics stock split history database.
Looking at the Relay Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Relay Therapeutics shares, starting with a $10,000 purchase of RLAY, presented on a split-history-adjusted basis factoring in the complete Relay Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/17/2020 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$43.98 |
|
| End price/share: |
$6.37 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-85.52% |
|
| Average Annual Total Return: |
-40.03% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,448.83 |
|
| Years: |
3.78 |
|
|
|
|
|
